Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
ImmaticsEli Lilly
Last price
$7.48$1,311.14
Currency
USD
USD
$1.1B$1.1T
-42.66
-$1.80$29.79
1.330.45
0$6.69
00.54%
Sector
HealthHealth
Employees
70450,000
Ticker
$IMTX$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $IMTX or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.